Memantine Augmentation in a Down's Syndrome Adolescent with Treatment- Resistant Obsessive-Compulsive Disorder

Aboujaoude E , Barry JJ , Gamel N : Memantine augmentation in treatment resistant obsessive-compulsive disorder: An open-label trial. J Clin Psychopharmacol, 29:51–55, 2009.

Abudy A , Juven-Wetzler A , Zohar J . Pharmacological management of treatment-resistant obsessive-compulsive disorder. CNS Drugs, 25:585–596, 2011.

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.

Capone G , Goyal P , Ares W , Lannigan E : Neurobehavioral disorders in children, adolescents, and young adults with Down syndrome. Am J Med Genet C Semin Med Genet, 142C:158–172, 2006.

Charlot L , Fox S , Friedlander R : Obsessional slowness in Down's syndrome. J Intellect Disabil Res, 46:517–524, 2002.

Choi DW . Excitotoxic cell death. J Neurobiol, 23:1261–1276, 1992.

Coric V , Taskiran S , Pittenger C , Wasylink S , Mathalon DH , Valentine G , Saksa J , Wu YT , Gueorguieva R , Sanacora G , Malison RT , Krystal JH : Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial. Biol Psychiatry, 58:424–428, 2005.

Grant P , Lougee L , Hirschtritt M , Swedo SE . An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol, 17:761–767, 2007.

Hezel DM , Beattie K , Stewart SE . Memantine as an augmenting agent for severe pediatric OCD. Am J Psychiatry, 166:237, 2009.

Mohan M , Bennett C , Carpenter PK : Memantine for dementia in people with Down syndrom. Cochrane Database of Stematic Reviews, 2009, Issue 1, Art. No: CD07657. DOI: 10.1002/14651858.CD007657.

O'Dwyer J , Holmes J , Collacott RA . Two cases of obsessive-compulsive disorder in individuals with Down's syndrome. J Nerv Ment Dis, 180:603–604, 1992.

Parsons CG , Stöffler A , Danysz W : Memantine: A NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system—too little activation is bad, too much is even worse. Neuropharmacology, 53:699–723, 2007.

Pasquini M , Biondi M . Memantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry, 30:1173–1175, 2006.

Pediatric OCD Treatment Study (POTS) Team: Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA, 292:1969–1976, 2004.

Pittenger C , Bloch MH , Williams K . Glutamate abnormalities in obsessive compulsive disorder: Neurobiology, pathophysiology, and treatment. Pharmacol Ther, 132:314–332, 2011.

Poyurovsky M , Weizman R , Weizman A , Koran L : Memantine for treatment-resistant OCD. Am J Psychiatry, 162:2191–2192, 2005.

Prasher VP : Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: Implications for the intellectual disability population. Int J Geriatr Psychiatry, 19:509–515, 2004.

Prasher VP , Day S : Brief report: obsessive-compulsive disorder in adults with Down's Syndrome. J Autism Dev Disord, 25:453–458, 1995.

Stewart SE , Jenike EA , Hezel DM , Stack DE , Dodman NH , Shuster L , Jenike MA : A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol, 30:34–39, 2010.

Sutor B , Hansen MR , Black JL . Obsessive compulsive disorder treatment in patients with Down syndrome: a case series. Downs Syndr Res Pract, 10:1–3, 2006.

Wu K , Hanna GL , Rosenberg DR , Arnold PD . The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav, 100:726–735, 2012.